118 related articles for article (PubMed ID: 3756934)
1. Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline.
Bajorin DF; Bosl GJ; Alcock NW; Niedzwiecki D; Gallina E; Shurgot B
Cancer Res; 1986 Nov; 46(11):5969-72. PubMed ID: 3756934
[TBL] [Abstract][Full Text] [Related]
2. Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated with cis-diamminedichloroplatinum(II).
Dumas M; de Gislain C; d'Athis P; Chadoint-Noudeau V; Escousse A; Guerrin J; Autissier N
Cancer Chemother Pharmacol; 1990; 26(4):278-82. PubMed ID: 2369792
[TBL] [Abstract][Full Text] [Related]
3. Effect of para-aminobenzoic acid on the pharmacokinetics and urinary excretion of cis-diamminedichloroplatinum(II) in rats.
Esposito M; Vannozzi M; Viale M; Pellecchia C; Civalleri D; Gogioso L
Anticancer Res; 1995; 15(6B):2541-7. PubMed ID: 8669820
[TBL] [Abstract][Full Text] [Related]
4. High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity.
Ostrow S; Egorin MJ; Hahn D; Markus S; Aisner J; Chang P; LeRoy A; Bachur NR; Wiernik PH
Cancer Treat Rep; 1981; 65(1-2):73-8. PubMed ID: 6784924
[TBL] [Abstract][Full Text] [Related]
5. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
6. Renal handling of cis-diamminedichloroplatinum(II).
Jacobs C; Kalman SM; Tretton M; Weiner MW
Cancer Treat Rep; 1980; 64(12):1223-6. PubMed ID: 7193518
[TBL] [Abstract][Full Text] [Related]
7. Hypertonic-hyperoncotic solutions improve cardiac function in children after open-heart surgery.
Schroth M; Plank C; Meissner U; Eberle KP; Weyand M; Cesnjevar R; Dötsch J; Rascher W
Pediatrics; 2006 Jul; 118(1):e76-84. PubMed ID: 16751617
[TBL] [Abstract][Full Text] [Related]
8. Hydration regimen and hematological toxicity of a cisplatin-based chemotherapy regimen. Clinical observations and pharmacokinetic analysis.
Numico G; Benasso M; Vannozzi MO; Merlano M; Rosso R; Viale M; Esposito M
Anticancer Res; 1998; 18(2B):1313-8. PubMed ID: 9615808
[TBL] [Abstract][Full Text] [Related]
9. Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum(II) (NSC 119875) to dogs.
Litterst CL; Gram TE; Dedrick RL; Leroy AF; Guarino AM
Cancer Res; 1976 Jul; 36(7 PT 1):2340-4. PubMed ID: 1277140
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions.
Kurihara N; Kubota T; Hoshiya Y; Otani Y; Ando N; Kumai K; Kitajima M
J Surg Oncol; 1996 Jun; 62(2):135-8. PubMed ID: 8649040
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients.
Specenier PM; Ciuleanu T; Latz JE; Musib LC; Darstein CL; Vermorken JB
Cancer Chemother Pharmacol; 2009 Jul; 64(2):233-41. PubMed ID: 19011858
[TBL] [Abstract][Full Text] [Related]
12. [Study on changes in plasma platinum concentrations after administration of CDDP to maintenance hemodialysis patients].
Suwata J; Hiraga S; Hida M; Takamiya T; Iida T; Sato T
Gan To Kagaku Ryoho; 1988 Feb; 15(2):243-8. PubMed ID: 3341786
[TBL] [Abstract][Full Text] [Related]
13. [The effect of bismuth subnitrate on cisplatin toxicity].
Chen JT; Kurokawa Y; Nakayama K; Saito K; Sakamoto K; Fukuda K; Hirai Y; Hamada T; Fujimoto I; Yamauchi K
Nihon Sanka Fujinka Gakkai Zasshi; 1987 May; 39(5):815-22. PubMed ID: 3298471
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetics of cis-dichlorodiammine platinum (II) in patients undergoing hemodialysis].
Miyakawa M; Sugimoto K; Ohe Y; Masuoka H; Miyahara T
Gan To Kagaku Ryoho; 1987 Aug; 14(8):2491-5. PubMed ID: 3619461
[TBL] [Abstract][Full Text] [Related]
15. [Effects of combination chemotherapy with cis-diamminedichloroplatinum (II) (CDDP) on renal function in patients with urogenital malignancies].
Kawamura J; Hida S; Higashi Y; Yamauchi T; Soeda A; Yoshida O
Hinyokika Kiyo; 1985 Feb; 31(2):207-21. PubMed ID: 4040315
[TBL] [Abstract][Full Text] [Related]
16. High-dose cisplatin in hypertonic saline: reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group Pilot Study in non-small-cell lung cancer.
Gandara DR; DeGregorio MW; Wold H; Wilbur BJ; Kohler M; Lawrence HJ; Deisseroth AB; George CB
J Clin Oncol; 1986 Dec; 4(12):1787-93. PubMed ID: 3023557
[TBL] [Abstract][Full Text] [Related]
17. Model independent pharmacokinetic study of cis-dichlorodiammineplatinum (II).
Dumas M; d'Athis P; de Gislain C; Escousse A; Guerrin J; Autissier N
Int J Clin Pharmacol Ther Toxicol; 1985 Aug; 23(8):430-3. PubMed ID: 4044076
[TBL] [Abstract][Full Text] [Related]
18. A bioassay of cisplatin by human tumor clonogenic assay.
Sasaki Y; Saijo N; Lee YC; Takahashi H; Ishihara J; Sakurai M; Sano T; Nakano H; Kanzawa F; Hoshi A
Jpn J Cancer Res; 1986 May; 77(5):494-501. PubMed ID: 3089981
[TBL] [Abstract][Full Text] [Related]
19. [Combination effects of cis-dichlorodiammineplatinum (II) and sodium thiosulfate on renal dysfunction].
Hirosawa A; Sakai S; Iizuka K; Niitani H; Hayashibara K; Tsuboi E
Gan To Kagaku Ryoho; 1987 Oct; 14(10):2870-5. PubMed ID: 3662543
[TBL] [Abstract][Full Text] [Related]
20. [Preventive effect of urinastatin on cisplatin induced nephrotoxicity in rabbits].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Mar; 41(3):328-32. PubMed ID: 2567322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
